These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 32334339)
1. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma. Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339 [TBL] [Abstract][Full Text] [Related]
2. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074 [TBL] [Abstract][Full Text] [Related]
3. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367 [TBL] [Abstract][Full Text] [Related]
4. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414 [TBL] [Abstract][Full Text] [Related]
5. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704 [TBL] [Abstract][Full Text] [Related]
6. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393 [TBL] [Abstract][Full Text] [Related]
7. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777 [TBL] [Abstract][Full Text] [Related]
8. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753 [TBL] [Abstract][Full Text] [Related]
9. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108 [TBL] [Abstract][Full Text] [Related]
10. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Chiaravalloti A; Danieli R; Abbatiello P; Di Pietro B; Travascio L; Cantonetti M; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1123-32. PubMed ID: 24562647 [TBL] [Abstract][Full Text] [Related]
11. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332 [TBL] [Abstract][Full Text] [Related]
12. The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD. Ingley KM; Nadel HR; Potts JE; Wilson DC; Eftekhari A; Deyell RJ J Pediatr Hematol Oncol; 2020 Mar; 42(2):e87-e93. PubMed ID: 31259825 [TBL] [Abstract][Full Text] [Related]
13. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746 [TBL] [Abstract][Full Text] [Related]
14. A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. Luminari S; Donati B; Casali M; Valli R; Santi R; Puccini B; Kovalchuk S; Ruffini A; Fama A; Berti V; Fragliasso V; Zanelli M; Vergoni F; Versari A; Rigacci L; Merli F; Ciarrocchi A Clin Cancer Res; 2020 Jan; 26(2):373-383. PubMed ID: 31645353 [TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036 [TBL] [Abstract][Full Text] [Related]
16. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Stephens DM; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; LaCasce AS; Barr PM; Knopp MV; Hsi ED; Leonard JP; Kahl BS; Smith SM; Friedberg JW Blood; 2019 Oct; 134(15):1238-1246. PubMed ID: 31331918 [TBL] [Abstract][Full Text] [Related]
17. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S; Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146 [TBL] [Abstract][Full Text] [Related]
18. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Sher DJ; Mauch PM; Van Den Abbeele A; LaCasce AS; Czerminski J; Ng AK Ann Oncol; 2009 Nov; 20(11):1848-53. PubMed ID: 19541793 [TBL] [Abstract][Full Text] [Related]
20. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. Johnson P; Federico M; Kirkwood A; Fosså A; Berkahn L; Carella A; d'Amore F; Enblad G; Franceschetto A; Fulham M; Luminari S; O'Doherty M; Patrick P; Roberts T; Sidra G; Stevens L; Smith P; Trotman J; Viney Z; Radford J; Barrington S N Engl J Med; 2016 Jun; 374(25):2419-29. PubMed ID: 27332902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]